Sugammadex 100 MG/ML [Bridion]
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Respiratory Complication
Conditions
Respiratory Complication, Obstructive Sleep Apnea
Trial Timeline
Feb 18, 2022 → May 7, 2025
NCT ID
NCT04263363About Sugammadex 100 MG/ML [Bridion]
Sugammadex 100 MG/ML [Bridion] is a approved stage product being developed by Merck for Respiratory Complication. The current trial status is completed. This product is registered under clinical trial identifier NCT04263363. Target conditions include Respiratory Complication, Obstructive Sleep Apnea.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04263363 | Approved | Completed |
Competing Products
20 competing products in Respiratory Complication
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Zopapogene imadenovec (Zopa) | Precigen | Approved | 80 |
| PRGN-2012 - Phase I; Dose Level 1 + PRGN-2012 - Phase I; Dose Level 2 + PRGN-2012 - Phase II; Dose Level 2 | Precigen | Phase 1/2 | 36 |
| agenT-797 | MiNK Therapeutics | Phase 1 | 25 |
| YMC026 + Placebo | Yuhan | Approved | 85 |
| VN-0200 + Placebo | Daiichi Sankyo | Phase 1 | 33 |
| VN-0200 | Daiichi Sankyo | Phase 2 | 52 |
| Isavuconazonium Injection [Cresemba] + Placebo | Astellas Pharma | Phase 3 | 77 |
| S-337395 + Placebo | Shionogi | Phase 2 | 52 |
| Sivelestat | Eli Lilly | Phase 1/2 | 41 |
| Itolizumab IV infusion + Best supportive care (BSC) | Biocon | Phase 2 | 52 |
| Paracetamol 500 mg/Phenylephrine 5 mg tablets + Paracetamol 1000 mg/Phenylephrine 10 mg sachet | Johnson & Johnson | Phase 1 | 33 |
| Mesenchymal stem cell | Rohto Pharmaceutical | Phase 1 | 33 |
| Palivizumab | AbbVie | Phase 3 | 77 |
| Palivizumab | AbbVie | Phase 3 | 77 |
| Placebo + AZD5634 | AstraZeneca | Phase 1 | 33 |
| MEDI8897 + Palivizumab | AstraZeneca | Phase 2/3 | 65 |
| Selumetinib + Durvalumab | AstraZeneca | Phase 2 | 52 |
| Tozorakimab + Placebo | AstraZeneca | Phase 3 | 77 |
| Nirsevimab | AstraZeneca | Phase 3 | 77 |
| Nirsevimab + Placebo | AstraZeneca | Phase 3 | 77 |